One of the leading clinical-stage immunotherapy companies, TapImmune Inc. (OTCMKTS:TPIV), attended fifth annual conference named “Cancer Immunotherapy: A Long-Awaited Reality” on Thursday March 26, 2015.” The conference was held at the New York Academy of Medicine in New York. Due to its second to none discoveries, the market performance of the company has been amazing for the past few months. It surged 15.25% on Monday and ended the day at $0.340.
Insights of Matter:
TapImmune specializes in the development of various innovative technologies for the treatment of infectious diseases and cancer. The primary objective of this presence was to present its corporate updates to all the stakeholders.
As per the reports, Dr. Glynn Wilson, Chief Executive Officer and Chairman, TapImmune was the spokesperson for the company at the event. The company had also made available the audio file of Wilson’s presentation on its official website for all the shareholders so that they could get the updates about the event, in case they missed it.
Apart from presenting corporate updates, Dr. Wilson will also participate in a panel discussion titled “What is the Role of Cancer Vaccines in an Environment Overwhelmed by Checkpoint Inhibitors and T Cell Immunotherapy.” The conference on cancer immunotherapy was a long awaited event in the New York City for individuals as well as corporate houses.
A wide range of visionary researchers, business leaders, clinicians, key investors, and various other stakeholders took part in this one-day long event. The primary objective of them behind taking part in this event was to make it a huge success and to share their knowledge with each other.
The conference was a perfect platform for all those companies that were active in the medical field with a special focus on finding a suitable cure for cancer. The management of TapImmune Inc. (OTCMKTS:TPIV) felt delighted to attend this event and hoped to take part in other such initiatives in the future.
